Skip to main content
. 2019 Aug 5;14(8):e0220413. doi: 10.1371/journal.pone.0220413

Fig 4. Kaplan–Meier plot for the relapse in patients with ulcerative colitis who achieved clinical remission and mucosal healing by treatment with budesonide foam in phase 2 or phase 3 clinical trials in Japan by a covariate.

Fig 4

(A) endoscopic subscore: MES = 0 (broken line) and MES = 1 (solid line) at start of this study, each median survival time (year) was 1.02 (95% CI: 0.61 to 1.66) and 0.54 (95% CI: 0.23 to 1.95), respectively. There was no significant difference between the groups (log-rank test, P = 0.275). (B) The disease duration: duration of <1 year(broken line), duration of 1–5 years (solid line), duration of ≥5 years (thin solid line). Each median survival times (year) were 0.28 (95% CI: 0.17 to 1.03), 0.97 (95% CI: 0.49 to 1.97), 0.93 (95% CI: 0.40 to 1.66), respectively. There was no significant difference between Group 1, 2 and 3 (log-rank test, P = 0.055). (C) Patients receiving budesonide foam, QD (broken line) and BID (solid line), each median survival times (year) were 0.54 (95% CI: 0.19 to 1.02) and 1.03 (95% CI: 0.61 to 1.83), respectively. There was no significant difference between Group 1 and Group 2 (log-rank test, P = 0.106).